We gratefully acknowledge the generous support provided by the conference sponsors:
Silver Sponsors
Cepheid: Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics — and we’ve never looked back. The GeneXpert® System has been heralded as game-changing by healthcare leaders across the globe — enabling institutions of any size, from small medical clinics to high-volume reference laboratories and hospitals, to access the speed and accuracy of molecular diagnostics. Cepheid’s growing Xpert® test menu spans multiple clinical applications including healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology.
Email: salesuk@cepheid.com
Phone: 01628 564000
Website: www.cepheid.com
MinervaX: MinervaX is developing a group B Strep vaccine based on a family of surface proteins found on 99.7% of clinical isolates. It is highly immunogenic, resulting in long-lasting high titres of functionally active antibodies. The vaccine has been tested in 300 healthy adult women and is currently being tested in pregnant women in Africa.
Contact: Dr Per Fischer, CEO
Email: pbf@minervax.com
Address: Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark
Website: www.minervax.com
Bronze Sponsors
Slater and Gordon: Slater and Gordon is one of the UK’s leading consumer law firms, committed to delivering exceptional, affordable legal services. With a reputation built on more than 90 years’ experience, we are one of the most successful medical negligence teams in the country, who specialise in all types of medical negligence claims, particularly in birth injury claims. We are committed to pursuing the best outcomes for our clients. We are extremely proud to stand with Group B Strep Support as a trusted legal partner and to support this dynamic charity in continuing its fight for prevention and awareness.
Contact: Laura Preston, Principal Lawyer
Email: LJPreston@slatergordon.co.uk
Website: www.slatergordon.co.uk
Nexsen: At Nexsen, we are driven to help eradicate the devastating impact of Group B Streptococcus (GBS) through our flagship StrepSure® rapid point-of-care test, which will deliver lab-grade accuracy in just 15-20 minutes during labor.
GBS silently causes 1 in 10 stillbirths and neonatal sepsis globally, yet prenatal screening misses critical intrapartum bacterial changes, leaving clinicians without real-time data.
StrepSure® addresses a critical unmet need by enabling clinicians to make real‑time decisions that reduce infection risks and minimize the use of antibiotics.
Contact: Mark Muzzin, Managing Director
Email: mm@nexsen.bio
Website: www.nexsen.bio
